心源性休克治疗与结局的性别差异:系统评价与流行病学荟萃分析
本系统评价与流行病学荟萃分析检索Cochrane Central、PubMed、MEDLINE和EMBASE(2024年4月),纳入81项随机对照试验或观察性研究,共65万6754例女性与101万8036例男性成人心源性休克患者,比较30天死亡率和机械循环支持使用率的性别差异。未校正分析显示女性合并院内及30天死亡风险高于男性(OR 1.35,95%CI 1.26-1.44,p<0.001),汇总死亡率男性35.9%、女性40.8%(p<0.001);仅纳入报告校正OR的研究后,女性死亡风险仍较高(OR 1.10,95%CI 1.06-1.15,p<0.001),在急性心肌梗死相关和心力衰竭相关心源性休克亚组中结果一致。女性接受机械循环支持的比例低于男性(OR 0.67,95%CI 0.57-0.79,p<0.001),其中主动脉内球囊反搏(OR 0.79,95%CI 0.71-0.89,p<0.001)和体外膜氧合(OR 0.84,95%CI 0.71-0.99,p=0.045)使用率较低,经皮心室辅助装置无显著差异(OR 0.82,95%CI 0.51-1.33,p=0.42)。作者据此认为临床医生应努力确保女性心源性休克患者得到及时诊断和积极治疗。
要点
- 在校正混杂因素后,女性心源性休克患者合并院内/30天死亡风险仍高于男性(OR 1.10,95%CI 1.06-1.15,p<0.001)。
- 未校正汇总死亡率男性为35.9%、女性为40.8%(p<0.001);未校正死亡OR为1.35(95%CI 1.26-1.44,p<0.001)。
- 女性接受机械循环支持的比例低于男性(OR 0.67,95%CI 0.57-0.79,p<0.001)。
- 女性接受主动脉内球囊反搏(OR 0.79,95%CI 0.71-0.89,p<0.001)和体外膜氧合(OR 0.84,95%CI 0.71-0.99,p=0.045)的比例低于男性,经皮心室辅助装置使用无显著差异(OR 0.82,95%CI 0.51-1.33,p=0.42)。
- 急性心肌梗死相关和心力衰竭相关心源性休克亚组中,女性死亡风险升高的结果保持一致。
适用人群与场景
- 纳入随机对照试验或观察性研究中的成年心源性休克患者,按性别分析死亡率或机械循环支持使用情况。
- 急性心肌梗死相关和心力衰竭相关心源性休克为原文报告的两个亚组。
研究设计与关键结果
- 研究类型为系统评价与流行病学荟萃分析,共纳入81项研究,合计65万6754例女性和101万8036例男性心源性休克患者。
- 未校正分析中,女性合并院内及30天死亡风险高于男性(OR 1.35,95%CI 1.26-1.44,p<0.001);汇总死亡率男性35.9% vs 女性40.8%(p<0.001)。
- 仅纳入报告校正OR的研究,女性合并院内/30天死亡风险仍高于男性(OR 1.10,95%CI 1.06-1.15,p<0.001)。
- 女性接受机械循环支持的比例低于男性(OR 0.67,95%CI 0.57-0.79,p<0.001);主动脉内球囊反搏使用OR 0.79(95%CI 0.71-0.89,p<0.001),体外膜氧合使用OR 0.84(95%CI 0.71-0.99,p=0.045),经皮心室辅助装置使用无显著差异(OR 0.82,95%CI 0.51-1.33,p=0.42)。
- 急性心肌梗死相关和心力衰竭相关心源性休克亚组中,女性死亡风险升高的结果保持一致。
证据类型、等级与局限
- 证据类型为系统评价与流行病学荟萃分析。
- 作者在结论中指出,即使校正混杂因素,女性心源性休克死亡率仍较男性高约10%,且女性接受机械循环支持的比例更低。
- 作者认为临床医生应立即努力确保女性心源性休克患者得到及时诊断和积极治疗。
对床旁实践的改变
- 研究结果提示,女性心源性休克患者校正后死亡风险仍较男性高约10%,且接受机械循环支持的比例更低。
- 作者认为,临床医生应努力确保女性心源性休克患者得到及时诊断和积极治疗。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Women are at higher risk of mortality from many acute cardiovascular conditions, but studies have demonstrated differing findings regarding the mortality of cardiogenic shock in women and men. To examine differences in 30-day mortality and mechanical circulatory support use by sex in patients with cardiogenic shock.
MAIN BODY: Cochrane Central, PubMed, MEDLINE and EMBASE were searched in April 2024. Studies were included if they were randomised controlled trials or observational studies, included adult patients with cardiogenic shock, and reported at least one of the following outcomes by sex: raw mortality, adjusted mortality (odds ratio) or use of mechanical circulatory support. Out of 4448 studies identified, 81 met inclusion criteria, pooling a total of 656,754 women and 1,018,036 men. In the unadjusted analysis for female sex and combined in-hospital and 30-day mortality, women had higher odds of mortality (Odds Ratio (OR) 1.35, 95% confidence interval (CI) 1.26-1.44, p < 0.001). Pooled unadjusted mortality was 35.9% in men and 40.8% in women (p < 0.001). When only studies reporting adjusted ORs were included, combined in-hospital/30-day mortality remained higher in women (OR 1.10, 95% CI 1.06-1.15, p < 0.001). These effects remained consistent across subgroups of acute myocardial infarction- and heart failure- related cardiogenic shock. Overall, women were less likely to receive mechanical support than men (OR = 0.67, 95% CI 0.57-0.79, p < 0.001); specifically, they were less likely to be treated with intra-aortic balloon pump (OR = 0.79, 95% CI 0.71-0.89, p < 0.001) or extracorporeal membrane oxygenation (OR = 0.84, 95% 0.71-0.99, p = 0.045). No significant difference was seen with use of percutaneous ventricular assist devices (OR = 0.82, 95% CI 0.51-1.33, p = 0.42).
CONCLUSION: Even when adjusted for confounders, mortality for cardiogenic shock in women is approximately 10% higher than men. This effect is seen in both acute myocardial infarction and heart failure cardiogenic shock. Women with cardiogenic shock are less likely to be treated with mechanical circulatory support than men. Clinicians should make immediate efforts to ensure the prompt diagnosis and aggressive treatment of cardiogenic shock in women.
参考来源
- Fisher T, Hill N, Kalakoutas A, et al. Sex differences in treatments and outcomes of patients with cardiogenic shock: a systematic review and epidemiological meta-analysis. Crit Care. 2024. PMID: 38845019. doi:10.1186/s13054-024-04973-5
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。